Literature DB >> 23266402

Inhaled Dornase alfa (Pulmozyme) as a noninvasive treatment of atelectasis in mechanically ventilated patients.

Jessica Nutik Zitter1, Pierre Maldjian, Michael Brimacombe, Kevin P Fennelly.   

Abstract

BACKGROUND: Lobar or segmental collapse of the lung in mechanically ventilated patients is a common occurrence in the intensive care unit. Management is labor and time intensive and not highly effective.
METHODS: We conducted a randomized, placebo-controlled, double-blind pilot study to determine whether nebulized Dornase alfa improves radiologic and clinical outcomes in ventilated patients with lobar atelectasis. Drug or placebo was administered twice daily until extubation, death, or transfer. The primary outcome was the total chest x-ray score: secondary outcomes of interest were oxygenation, lung compliance, and rate of extubation over the first 5 days. The groups consisted of 14 intervention patients and 16 control patients.
RESULTS: There were no significant differences in "Total Chest X-Ray Score" or compliance over the 5 days of study. There was an improvement in oxygenation for the intervention group at day 5 (P = .03). In addition, this group was less likely to remain intubated over the first 24 hours of the study, a difference that did not persist over the course of the study.
CONCLUSIONS: Dornase alfa does not improve the appearance of atelectasis on chest radiographs, or the "Total Chest X-Ray Score" over the first 5 days of treatment in mechanically ventilated patients. The intervention group's higher rate of extubation during the first 24 hours as well as its improved oxygenation on day 5 were likely chance findings given the multiple potential confounders for extubation and low study power.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23266402     DOI: 10.1016/j.jcrc.2012.09.015

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  7 in total

1.  Impact of Clinical, Unit-Specific Guidelines on Dornase Alfa Use in Critically Ill Pediatric Patients Without Cystic Fibrosis.

Authors:  Carson Tester; Doug Raiff; Travis Heath
Journal:  Hosp Pharm       Date:  2019-03-15

Review 2.  Fundamentals of aerosol therapy in critical care.

Authors:  Jayesh Dhanani; John F Fraser; Hak-Kim Chan; Jordi Rello; Jeremy Cohen; Jason A Roberts
Journal:  Crit Care       Date:  2016-10-07       Impact factor: 9.097

3.  Efficacy of ventilator for patients with atelectasis: A systematic review protocol of randomized controlled trials.

Authors:  Zhi-Guo Wang; Jian-Rong Sun; Hai-Wang Sha
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

4.  Elastase and exacerbation of neutrophil innate immunity are involved in multi-visceral manifestations of COVID-19.

Authors:  Jean-Louis Guéant; Rosa-Maria Guéant-Rodriguez; Julien Fromonot; Abderrahim Oussalah; Huguette Louis; Celine Chery; Mickael Gette; Stanislas Gleye; Jonas Callet; Jeremie Raso; François Blanchecotte; Patrick Lacolley; Régis Guieu; Véronique Regnault
Journal:  Allergy       Date:  2021-02-27       Impact factor: 14.710

Review 5.  Mucus Clearance Strategies in Mechanically Ventilated Patients.

Authors:  Ryan L Goetz; Kadambari Vijaykumar; George M Solomon
Journal:  Front Physiol       Date:  2022-03-23       Impact factor: 4.566

Review 6.  Nebulised dornase alfa versus placebo or hypertonic saline in adult critically ill patients: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis.

Authors:  Casper Claudius; Anders Perner; Morten Hylander Møller
Journal:  Syst Rev       Date:  2015-11-08

7.  Protocol for TRAUMADORNASE: a prospective, randomized, multicentre, double-blinded, placebo-controlled clinical trial of aerosolized dornase alfa to reduce the incidence of moderate-to-severe hypoxaemia in ventilated trauma patients.

Authors:  Julien Pottecher; Eric Noll; Marie Borel; Gérard Audibert; Sébastien Gette; Christian Meyer; Elisabeth Gaertner; Vincent Legros; Raphaël Carapito; Béatrice Uring-Lambert; Erik Sauleau; Walter G Land; Seiamak Bahram; Alain Meyer; Bernard Geny; Pierre Diemunsch
Journal:  Trials       Date:  2020-03-18       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.